MK-2206 is a potent, orally active allosteric Akt inhibitor with IC50 of 5/12 nM for Akt1/Akt2 respectively. MK-2206 shows 5-fold less potent against human Akt3 (IC50=65 nM). MK-2206 synergistically inhibits cell proliferation of human cancer cell lines in combination with erlotinib or lapatinib in vitro. MK-2206 suppresses the Akt phosphorylation that is induced by carboplatin and gemcitabine.
